Picard Medical Shares Rise 15% After Acute Animal Studies of Emperor Total Artificial Heart
Picard Medical, Inc. shares climbed 15% to $0.31 after Tuesday's close following positive results from acute in vivo implant studies of its next-generation Emperor Total Artificial Heart platform.
prnewswire.comPicard Medical, Inc. 31 in after-hours trading on Tuesday following the company's announcement of successful acute in vivo implant studies of its Emperor Total Artificial Heart platform. The Tucson-based company, which trades on the NYSE under the ticker PMI, said the procedures took place at the University of Arizona and Banner University Medical Center.
Three procedures demonstrated stable hemodynamic support with no device-related intraoperative failures. The Emperor TAH uses an independent dual-motor ventricular design that allows side-specific control of systemic and pulmonary circulation. The platform builds on the architecture and clinical experience of the company's SynCardia Total Artificial Heart, which holds FDA and Health Canada approval.
CEO Patrick Schnegelsberg described the results as "another important milestone" toward a fully implantable heart. The Emperor TAH has not yet received FDA approval. Benzinga reported that Picard Medical was listed among Tuesday's top biotech gainers.
RTT News also identified the company among healthcare sector leaders that day.
Transparency
2 independent outlets report the same core facts. This score blends how many outlets corroborate, their editorial tier, and how closely their facts agree — it measures corroboration, not proof.
Story details
Related Stories
ForbesNASA Retires MAVEN After 11 Years of Mars Atmosphere Discoveries Following Unrecoverable Anomaly
The agency confirmed Wednesday that the orbiter, launched in 2013, is beyond recovery following a fast spin that drained its batteries. MAVEN completed more than a decade of atmospheric observations at Mars.
foxnews.comTrump Budget Reduces CDC Wastewater Surveillance Funding From $125M to $25M Annually
President Donald Trump's budget plan reduces annual funding for the CDC's National Wastewater Surveillance System from $125 million to $25 million, limiting national coverage after September 30, 2026.